KdT Ventures participated in a US$12 million top-up financing for Reverb Therapeutics, a company developing a next-generation anti-PD-1 bispecific antibody (AMP01) leveraging its Amplify•R platform for cancer and autoimmune disease treatment.
Reverb creates medicines that intelligently reshape the body’s immune system to fight cancer and other life-threatening conditions more effectively
Reverb creates medicines that intelligently reshape the body’s immune system to fight cancer and other life-threatening conditions more effectively. Their Amplify•R™ platform adjusts the volume and tunes the body’s natural immune system, enhancing anti-tumor activity without the harm associated with exogenous cytokine treatments.